Secondary metabolites as DNA topoisomerase inhibitors: A new era towards designing of anticancer drugs

Pharmacognosy Reviews

Volumn 4, Issue 7, 2010, Pages 12-26

  Baikar, Supriya ^a   Malpathak, Nutan ^a  

^a UNIVERSITY OF PUNE   (India)

Author keywords

Anticancer; DNA topoisomerases; flavonoids; secondary metabolities

Indexed keywords

ALKALOID; ALOE EMODIN; ALPHA LAPACHONE; ANTINEOPLASTIC AGENT; BETA LAPACHONE; CAMPTOTHECIN; CHALCONE; CHELERYTHINE; DIOSPYRIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ELEUTHERIN; FAGARONINE; HARMALINE; HARMINE; IRINOTECAN; ISODIOSYPRIN; ISOFAGARIDINE; LIGNAN; NITIDINE; PACLITAXEL; PLANT MEDICINAL PRODUCT; PLUMBAGIN; POLYPHENOL; QUINONE DERIVATIVE; SHIKONIN; TERPENOID; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CYTOTOXICITY; DNA CLEAVAGE; DNA FRAGMENTATION; DNA SYNTHESIS INHIBITION; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; HUMAN; LEUKOCYTE; NAUSEA; NONHUMAN; PARESTHESIA; PLANT METABOLISM; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIDE EFFECT; SINGLE STRANDED DNA BREAK; SKIN TINGLING; STRUCTURE ACTIVITY RELATION;

EID: 77955697794     PISSN: None     EISSN: 09737847     Source Type: Journal    
DOI: 10.4103/0973-7847.65320     Document Type: Review

References (104)

1. Verpoorte R. Exploration of nature's chemodiversity: The role of secondary metabolites as leads in drug development. DDT 1998. p. 3.
2. Oksman-Caldentey KM, Inzé D. Plant cell factories in the post-genomic era: New ways to produce designer secondary metabolites. Trends Plant Sci 2004;9:433-440
3. Verpoorte R. Secondary metabolism. Metabolic Engineering of Plant Secondary Metabolism. In: Verpoorte R, Alfermann AW, editors. Kluwer Academic Publishers; 2000. p. 1-29.
4. Verpoorte R, Memelink J. Engineering secondary metabolite production in plants. Curr Opin Biotechnol 2002;13:181-187
5. Yazaki K. ABC transporters involved in the transport of plant secondary metabolites. FEBS Lett 2006;580:1183-1191
6. Mijts BN, Schmidt-Dannert C. Engineering of secondary metabolite pathways. Curr Opin Biotechnol 2003;14:597-602.
7. Cairns J. The chromosome of Escherichia coli. Cold Spring Harbor. Symp Quant Biol 1963;28:43-46
8. Wang JC. Interaction between DNA and an Escherichia coli protein omega. J Mol Biol 1971;55:523-533
9. Depew RE, Liu LF, Wang JC. Interaction between DNA and Escherichia coli protein omega: Formation of a complex between single-stranded DNA and omega protein. J Biol Chem 1978;253:511-518
10. Wang, JC, Liu, LF. DNA topoisomerases: Enzymes that catalyze the concerted breaking and rejoining of DNA backbone bonds J Molecular genetics, part III. Academic Press, Inc., New York, 1979, 65-88.
11. Champoux JJ, Dulbecco R. An activity from mammalian cells that untwists superhelical DNA: A possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryo cells-dye binding assay). Proc Natl Acad Sci\USA 1972;69:143-146
12. Gellert M, Mizuuchi K, O'Dea MH, Nash HA. DNA gyrase: An enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci\USA 1976;73:3872-3876
13. Liu LF, Liu CC, Alberts BM. T4 DNA topoisomerase. A new ATP-dependent enzyme essential for the initiation of T4 bacteriophage DNA replication. Nature 1979;281:456-461
14. Stetler GL, King GJ, Huang WM. T4 DNA-delay proteins, required for specifi c DNA replications, form a complex that has ATP-dependent DNA topoisomerase activity. Proc Natl Acad Sci\USA 1979;76:3737-3741
15. Bergerat A, Gadelle D, Forterre P. Purifi cation of a DNA topoisomerase II from the hyperthermophilic archaeon Sulfolobus shibatae: A thermostable enzyme with both bacterial and eucaryal features. J Biol Chem 1994;269:27663-27669
16. Bergerat A, de Massy B, Gadelle D, Varoutas PC, Nicolas A, Forterre P. An atypical topoisomerase II from Archaea with implications for meiotic recombination. Nature 1997;386:414-417
17. Srivenugopal KS, Lockshon D, Morris DR. Escherichia coil DNA topoisomerase III: Purifi cation and characterization of a new type I enzyme. Biochemistry 1984;23:1899-1906
18. Kim RA, Wang JC. Identifi cation of the yeast TOP3 gene product as a single strand-specifi c DNA topoisomerase. J Biol Chem 1992;267:17178-17185
19. Wallis JW, Chrebet G, Brodsky G, Rolfe M, Rothstein R. A hyper-recombination mutation in S. cerevisiae identifi es a novel eukaryotic topoisomerase. Cell 1989;58:409-419
20. Kato J, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H. New topoisomerase essential for chromosome segregation in E. coli. Cell 1990;63:393-404.
21. Kato J, Suzuki H, Ikeda H. Purifi cation and characterization of DNA topoisomerase IV in Escherichia coli. J Biol Chem 1992;267:25676-25684
22. Slesarev AI, Stetter KO, Lake JA, Gellert M, Krah R, Kozyavkin SA. DNA topoisomerase V is a relative of eukaryotic topoisomerase I from a hyperthermophilic prokaryote. Nature 1993;364:735-737
23. Pommier Y. Diversity of DNA topoisomerases I and inhibitors. Biochimie 1998;80:255-270
24. Champoux JJ. DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
25. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985;54:665-697
26. Roca J. The mechanisms of DNA topoisomerases. Trends Biochem Sci 1995;20:156-160
27. Liu LF. DNA topoisomerase poisons as antitumour drugs. Annu Rev Biochem 1989;58:351-375
28. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994;303:681-695
29. Nitiss JL. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim Biophys Acta 1998;1400:63-81.
30. Li W, Wang JC. Mammalian DNA topoisomerase IIIalpha is essential in early embryogenesis. Proc Natl Acad Sci\USA 1998;95:1010-1013
31. Berger JM. Structure of DNA topoisomerases. Biochim Biophys Acta 1998;1400:3-18.
32. Corbett KD, Berger JM. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct 2004;33:95-118.
33. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000;7:39-58.
34. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1998;1400:155-171
35. Bertram JS. The molecular biology of cancer. Mol Aspects Med 2000;21:167-223.
36. Chen AY, Liu LF. DNA topoisomerase: Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994;34:191-218.
37. Dholwani KK, Saluja AK, Gupta AR, Shah DR. A review on plant-derived natural products and their analogs with anti-tumor activity. Indian J Pharmacol 2008;40:49-58.
38. Facchini PJ, Bird DA, St-Pierre B. Can Arabidopsis make complex alkaloids? Trends Plant Sci 2004;9:116-122
39. Wall ME, Wani MC, Cooke CE, Palmer KH, Mcphail AT. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966;88:3888-3890
40. Srivastava V, Negi AS, Kumar JK, Gupta MM, Khanuja SP. Plant-based anticancer molecules: A chemical and biological profi le of some important leads. Bioorg Med Chem 2005;13:5892-5908
41. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-14878
42. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:83-105.
43. Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995;1262:1-14.
44. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: Current perspectives. Bioorg Med Chem 2004;12:1585-1604
45. Ewesuedo RB, Ratain MJ. Topoisomerase I inhibitors. Oncologist 1997;2:359-364
46. Fang SD, Wang LK, Hecht SM. Inhibitors of DNA topoisomerase I isolated from roots of Zanthoxylum nitidum. J Organic Chem 1993;19:5025-5027
47. Wang LK, Johnson RK, Hecht SM. Inhibition of topoisomerase I function by nitidine and fagaronine. Chem Res Toxicol 1993;6:813-818
48. Hazra B, Sur P, Roy DK, Sur B, Banerjee A. Biological activity of diospyrin towards Ehrlich ascites carcinoma in Swiss A mice. Planta Med 1984;50:295-297
49. Ray S, Hazra B, Mittra B, Das A, Majumder HK. Diospyrin, a bisnaphthoquinone: A novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Mol Pharmacol 1998;54:994-999
50. Pecere T, Gazzola MV, Mucignat C, Parolin C, Vecchia FD, Cavaggioni A, et al. Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. Cancer Res 2000;60:2800-2804
51. Hara H, Maruyama N, Yamashita S, Hayashi Y, Lee KH, Bastow KF, et al. Elecanacin, a novel new naphthoquinone from the bulb of Eleutherine americana. Chem Pharm Bull (Tokyo) 1997;45:1714-1716
52. Krishnan P, Bastow KF. Novel mechanisms of DNA topoisomerase II inhibition by pyranonaphthoquinone derivatives-eleutherin, alpha lapachone, and bet lapachone. Biochem Pharmacol 2000;60:1367-1379
53. Sobhani AM, Ebrahimi SA, Mahmoudian M. An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its β-carboline alkaloids. J Pharm Pharm Sci 2002;5:19-23.
54. Ting C Y, Hsu CT, Hsu HT, Su JS, Chen T Y, Tarn WY, et al. Isodiospyrin as a novel human DNA topoisomerase I inhibitor. Biochem Pharmacol 2003;66:1981-1991
55. Prescott TA, Sadler IH, Kiapranis R, Maciver SK. Lunacridine from Lunasia amara is a DNA intercalating topoisomerase II inhibitor. J Ethnopharmacol 2007;109:289-294
56. Son JK, Jung SJ, Jung JH, Fang Z, Lee CS, Seo CS, et al. Anticancer constituents from the roots of Rubia cordifolia L. Chem Pharm Bull (Tokyo) 2008;56:213-216
57. Fujii N, Yamashita Y, Arima Y, Nagashima M, Nakano H. Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin. Antimicrob Agents Chemother 1992;36:2589-2594
58. Thind TS, Agrawal SK, Saxena AK, Arora S. Studies on cytotoxic, hydroxyl radical scavenging and topoisomerase inhibitory activities of extracts of Tabernaemontana divaricata (L.) R.Br. ex Roem. and Schult. Food Chem Toxicol 2008;46:2922-2927
59. Croteau R, Kutchan TM, Lewis NG. Natural Products (Secondary Metabolites). Biochem Mole Biol Plants 2000;24:1250-1318
60. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-2327
61. Kingston DG. The chemistry of taxol. Pharmacol Ther 1991;52:1-34.
62. Geney R, Chen J, Ojima I. Recent advances in the new generation taxane anticancer agents. Med Chem 2005;1:125-139
63. Itokawa H, Morris-Natschke SL, Akiyama T, Lee KH. Plant-derived natural product research aimed at new drug discovery. J Nat Med 2008;62:263-280
64. Miyata S, Wang LY, Yoshida C, Kitanaka S. Inhibition of cellular proliferation by diterpenes, topoisomerase II inhibitor. Bioorg Med Chem 2006;14:2048-2051
65. Li CH, Chen PY, Chang UM, Kan LS, Fang WH, Tsai KS, et al. Ganoderic acid X, a lanostanoid triterpene, inhibits topoisomerases and induces apoptosis of cancer cells. Life Sci 2005;77:252-265
66. Meng LH, Zhang JS, Ding J. Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes. Biochem Pharmacol 2001;62:733-741
67. Tanaka N, Kitamura A, Mizushina Y, Sugawara F, Sakaguchi K. Fomitellic acids, triterpenoid inhibitors of eukaryotic DNA polymerases from a basidiomycete, Fomitella fraxinea. J Nat Prod 1998;61:193-197
68. Mizushina Y, Iida A, Ohta K, Sugawara F, Sakaguchi K. Novel triterpenoids inhibit both DNA polymerase and DNA topoisomerase. Biochem J 2000;350:757-763
69. Dixon RA, Steele CL. Flavonoids and isofl avonoids: A gold mine for metabolic engineering. Trends Plant Sci 1999;4:394-400.
70. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: A review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001;74:418-425
71. Akoi T, Akashi T, Ayabe S. Flavonoids of leguminous plants: Structure, biological activity and biosynthesis. J Plant Res 2000;113:475-488
72. López-Lázaro M. Flavonoids as anticancer agents: Structure-activity relationship study. Curr Med Chem Anticancer Agents 2002;2:691-714.
73. Jedinak A, Farago J, Psenakova I, Maliar T. Approaches to fl avonoid production in plant tissue cultures. Biologia Bratislava 2004;59:697-710
74. Messina MJ. Legumes and soybeans: Overview of their nutritional profi les and health effects. Am J Clin Nutr 1999;70:439S-50S.
75. Austin CA, Patel S, Ono K, Nakane H, Fisher LM. Site-specifi c DNA cleavage by mammalian DNA topoisomerase II induced by novel fl avone and catechin derivatives. Biochem J 1992;282:883-889
76. Constantinou A, Mehta R, Runyan C, Rao K, Vaughan A, Moon R. Flavonoids as DNA topoisomerase antagonists and poisons: Structure-activity relationships. J Nat Prod 1995;58:217-225
77. Boege F, Straub T, Kehr A, Boesenberg C, Christiansen K, Andersen A, et al. Selected novel fl avones inhibit the DNA binding or the DNA relegation step of eukaryotic topoisomerase I. J Biol Chem 1996;271:2262-2270
78. Bernard FX, Sablé S, Cameron B, Provost J, Desnottes JF, Crouzet J, et al. Glycosylated fl avones as selective inhibitors of topoisomerase IV. Antimicrob Agents Chemother 1997;41:992-998
79. Zahir A, Jossang A, Bodo B, Provost J, Cosson JP, Sévenet T. DNA topoisomerase I inhibitors: Cytotoxic fl avones from Lethedon tannaensis. J Nat Prod 1996;59:701-703
80. Sun NJ, Woo SH, Cassady JM, Snapka RM. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia J Nat Prod 1998;61:362-366
81. Dutta PK, Chowdhury US, Chakraborty AK, Achari B, Pakrashi SC. Studies on Indian medicinal plants: Nishindaside: a novel iridoid glycoside from Vitex negundo. Tetrahedron 1983;39:3067-3072
82. Chowdhury AR, Sharma S, Mandal S, Goswami A, Mukhopadhyay S, Majumder HK. Luteolin, an emerging anti-cancer fl avonoid, poisons eukaryotic DNA topoisomerase I. Biochem J 2002;366: 653-661
83. Cantero G, Campanella C, Mateos S, Cortés F. Topoisomerase II inhibition and high yield of endoreduplication induced by the fl avonoids luteolin and quercetin. Mutagenesis 2006;21:321-325
84. López-Lazaro M, Willmore E, Austin CA. Cells lacking DNA topoisomerase II beta are resistant to genistein. J Nat Prod 2007;70:763-767
85. Vega MR, Esteves-Souza A, Vieira IJ, Mathias L, Braz-Filhob R, Echevarria A. Flavonoids from Annona dioica leaves and their effects in Ehrlich carcinoma cells, DNA-topoisomerase I and II. J Braz Chem Soc 2007;18:1554-1559
86. Roupe KA, Remsberg CM, Yáñez JA, Davies NM. Pharmacometrics of stilbenes: Seguing towards the clinic. Curr Clin Pharmacol 2006;1:81-101.
87. Pettit GR, Cragg GM, Herald DL, Schmidt JM, Lohavanijaya P. Isolation and structure of combretastatin. Can J Chem 1982;60:1374.
88. Pettit GR, Singh SB, Cragg GM. Synthesis of natural (-)-Combretastatin. J Org Chem 1985;50:3404-3406
89. Pettit GR, Cragg GM, Singh SB. Antineoplastic agents, 122: Constituents of Combretum caffrum. J Nat Prod 1987;50:386-391
90. Hamel E, Lin CM. Interactions of combretastatin: a new plant-derived antimitotic agent, with tubulin. Biochem Pharmacol 1983;32:3864-3867
91. Lin CM, Ho HH, Pettit GR, Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989;28:6984-6991
92. Xu ML, Zheng MS, Lee YK, Moon DC, Lee CS, Woo MH, et al. A new stilbene glucoside from the roots of Polygonum multifl orum Thunb. Arch Pharm Res 2006;29:946-951
93. Yamada M, Hayashi K, Hayashi H, Tsuji R, Kakumoto K, Ikeda S, et al. Nepalensinols D-G, new resveratrol oligomers from Kobresia nepalensis (Cyperaceae) as potent inhibitors of DNA topoisomerase II. Chem Pharm Bull (Tokyo) 2006;54:354-358
94. Yoon G, Kang BY, Cheon SH. Topoisomerase I inhibition and cytotoxicity of licochalcones A and E from Glycyrrhiza infl ata. Arch Pharm Res 2007;30:313-316
95. Moss GP. Nomenclature of lignans and neolignans. Pure Appl Chem 2000;72:1493-1523
96. Imbert TF. Discovery of podophyllotoxins. Biochimie 1998;80: 207-222
97. Gordaliza M, Castro MA, del Corral JM, Feliciano AS. Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des 2000;6:1811-1839
98. Gordaliza M, García PA, del Corral JM, Castro MA, Gómez-Zurita MA. Podophyllotoxin: Distribution, sources, applications and new cytotoxic derivatives. Toxicon 2004;44:441-459
99. Ayres DC, Loike Lignans JD. Chemical, biological and clinical properties. Cambridge: Cambridge University Press; 1990.
100. Utsugi T, Shibata J, Sugimoto Y, Aoyagi K, Wierzba K, Kobunai T, et al. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res 1996;56:2809-2814
101. Subrahmanyam D, Renuka B, Rao CV, Sagar PS, Deevi DS, Babu JM, et al. Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents. Bioorg Med Chem Lett 1998;8: 1391-1396
102. Stähelin HF, von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain memorial Award lecture. Cancer Res 1991;51:5-15.
103. Li G, Lee CS, Woo MH, Lee SH, Chang HW, Son JK. Lignans from the bark of Machilus thunbergii and their DNA topoisomerases I and II inhibition and cytotoxicity. Biol Pharm Bull 2004;27:1147-1150
104. Kashiwada Y, Bastow KF, Lee K. Novel lignan derivatives as selective inhibitors of DNA topoisomerase II. Bioorg Med Chem Lett 1995;5:905-908